Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73430
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73430
Character Range: 17908–19437

73430              Fluorescence in‑situ hybridisation (FISH) test of tumour tissue from a patient with locally advanced or metastatic solid tumour, if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       400.00

                      (a) the tumour is at risk of being caused by a neurotrophic receptor tyrosine kinase (NTRK) gene fusion as determined by either:
                          (i) occurring in a child less than 18 years of age; or
                          (ii) being mammary analogue secretory carcinoma of the salivary gland; or
                          (iii) being secretory breast carcinoma; and

                      (b) the test is requested by a specialist or consultant physician to determine if requirements relating to NTRK gene fusion status for access to a tropomyosin receptor kinase (Trk) inhibitor under the Pharmaceutical Benefits Scheme are fulfilled

                   This item cannot be claimed if item 73433 has been claimed for the same patient during the same cancer diagnosis

                   Applicable only once per cancer diagnosis